#GoldenCross $JNCE at 9.21 R70 HiLo 92% T1Y 12 buy PE 4.0 DIV N/A #Jounce The #stocks #trading #finance #market

2019-12-14
142 Views

Golden Cross detected for JNCE (Jounce Therapeutics,) at the close price of 9.21. Trading at a 92 % level between the 52week High (9.80) and 52week Low (2.66). The average analyst 1-year target price is 12.0 with an average buy and a score of 0.0.

Golden Cross
70 %
JNCE
9.21
Jounce Therapeutics,
HiLo
91.7 %
Support
5.41
Resistance
9.21
50DMA
4.88
200DMA
4.82
52week high
9.80
52week low
2.66
10DMA
8.10
20DMA
6.54
100 Mean
4.34
Volume
795934
AvgDayVol
472545
MarketCap
306034496
EBITDA
77074000
Revenue
167972000
PE
4.02
P2S
1.82
P2B
0.00
Dividend
0.00
Div Ex-Date

Further research links:

Marketwatch Yahoo Finance Google Finance StockTwits

You may be interested

HILO Index 161 Current 64.35 MA20 -36.84 Lower 92.72 Upper Bound #stocks #trading #markets #finance
Bear, Global Indicators
2 views
Bear, Global Indicators
2 views

HILO Index 161 Current 64.35 MA20 -36.84 Lower 92.72 Upper Bound #stocks #trading #markets #finance

Andreas Aigner - 2020-08-12

[Bearish] HILO Index 161 Current 64.35 MA20 -36.84 Lower 92.72 Upper Bound #stocks #trading #markets #finance x

Demark B/S Index -17.68 Avg 57.08 Std -10 Curr #stocks #trading #markets #finance
Global Indicators,
Global Indicators,

Demark B/S Index -17.68 Avg 57.08 Std -10 Curr #stocks #trading #markets #finance

Andreas Aigner - 2020-08-12

Demark B/S Index -17.68 Avg 57.08 Std -10 Curr #stocks #trading #markets #finance

50/200 DMA Index -3.77 Avg 13.33 Std 2 Curr #stocks #trading #markets #finance
Global Indicators,
5 views
Global Indicators,
5 views

50/200 DMA Index -3.77 Avg 13.33 Std 2 Curr #stocks #trading #markets #finance

Andreas Aigner - 2020-08-12

50/200 DMA Index -3.77 Avg 13.33 Std 2 Curr #stocks #trading #markets #finance x

Leave a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

We use Cookies to improve our Site. Your are agreeing to this by continuing to use our Site.